A Peptide Antagonist of the TLR4–MD2 Interaction
- 24 February 2009
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 10 (4), 645-649
- https://doi.org/10.1002/cbic.200800769
Abstract
Toll‐like receptors are an integral part of innate immunity in the central nervous system (CNS); they orchestrate a robust defense in response to both exogenous and endogenous danger signals. Recently, toll‐like receptor 4 (TLR4) has emerged as a therapeutic target for the treatment of CNS‐related diseases such as sepsis and chronic pain. We herein report a chemical biology approach by using a rationally designed peptide inhibitor to disrupt the TLR4–MD2 association, thereby blocking TLR4 signaling.Keywords
This publication has 26 references indexed in Scilit:
- Protein Structure Prediction Using RosettaMethods in enzymology, 2004
- Neuroimmune Activation and Neuroinflammation in Chronic Pain and Opioid Tolerance/HyperalgesiaThe Neuroscientist, 2004
- TLR signaling pathwaysSeminars in Immunology, 2004
- Lysines 128 and 132 Enable Lipopolysaccharide Binding to MD-2, Leading to Toll-like Receptor-4 Aggregation and Signal TransductionJournal of Biological Chemistry, 2003
- Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathwayProceedings of the National Academy of Sciences, 2003
- Phosphatidylinositol 3‐kinase is involved in Toll‐like receptor 4‐mediated cytokine expression in mouse macrophagesEuropean Journal of Immunology, 2003
- The Danger Model: A Renewed Sense of SelfScience, 2002
- Native protein sequences are close to optimal for their structuresProceedings of the National Academy of Sciences, 2000
- Cellular Events Mediated by Lipopolysaccharide-stimulated Toll-like Receptor 4Published by Elsevier BV ,2000
- MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4The Journal of Experimental Medicine, 1999